Study on the inhibitory effect of ligustrazine on the proliferation and collagen production of human embryonic lung fibroblast MRC-5 / 国际中医中药杂志

Objective:To study the effect of ligustrazine on the proliferation and collagen production of human embryonic lung fibroblasts MRC-5.Methods:MRC-5 was cultured and divided into control group, low-dose group, medium-dose group and high-dose group. The control group was treated with DMEM without drugs, while the low-dose group, medium-dose group and high-dose group were treated with DMEM with different doses of ligustrazine. After 24, 36 and 48 h treatment, the cell proliferation activity was detected by MTS assay; the cell cycle was detect by flow cytometry; the apoptosis was measured by TUNEL staining; Western blot was used to detect the expression of Bcl-2, Bax, CyclinD1, P27 protein, and ELISA was used to detect the levels of TGF-β1, Col-Ⅰ and Col-Ⅲ.Results:After 24, 36 and 48 h treatment, compared to the control group, the proliferation inhibitory rate of low-, medium-, and high-dose group increased significantly ( P<0.05). After 48 h treatment, compared to the control group, the G0/G1 phase proportion of cell cycle in different doses of ligustrazine group significantly increased, and the S phase proportion of cell cycle in different doses of ligustrazine group significantly decreased ( P<0.05). Compared to the control group, the apoptosis rate (6.59% ± 0.95%, 10.92% ± 2.25%, 16.58% ± 3.25% vs. 1.38% ± 0.34%) in different doses of ligustrazine group significantly increased ( P<0.05). Compared to the control group, the expression of Bcl-2 (0.79 ± 0.13, 0.52 ± 0.06, 0.31 ± 0.05 vs. 0.91 ± 0.15) and CyclinD1 (0.62 ± 0.08, 0.50 ± 0.06, 0.27 ± 0.04 vs. 0.83 ± 0.14) in different doses of ligustrazine group significantly decreased, while the expression of Bax (0.45 ± 0.07, 0.50 ± 0.06, 0.79 ± 0.13 vs. 0.32 ± 0.06) and p27 (0.39 ± 0.07, 0.75 ± 0.13, 0.96 ± 0.16 vs. 0.20 ± 0.05) significantly increased ( P<0.05). The content of TGF-β1, Col-Ⅰ and Col-Ⅲ in different doses of ligustrazine group were significantly decreased ( P<0.05). Conclusions:Ligustrazine can inhibit the proliferation and collagen production of human embryonic lung fibroblasts, which may be related to the induction of cell cycle arrest, regulation of proliferation and cell cycle related proteins expression.

Prevalence and echocardiographic feature of bicuspid aortic valve in patients with severe aortic stenosis: a echocardiography database analysis / 中华心血管病杂志

<p><b>OBJECTIVE</b>To evaluate the accuracy of echocardiography in identifying aortic valve structures and determine the prevalence of bicuspid aortic valves (BAV) in severe aortic stenosis (AS) population to provide useful information for transcatheteraortic valve replacement (TAVR).</p><p><b>METHODS</b>A total of 300 AS patients undergoing surgical aortic valve replacement were included to determine the accuracy of transthoracic echocardiography in indentifying BAV from January 2009 to July 2013. The echocardiographic data of our hospital from 2004 to 2012 was retrospectively reviewed. 1 371 patients with isolated severe native aortic valves stenosis were consecutively enrolled.</p><p><b>RESULTS</b>The aortic valve structures could be defined by transthoracic echocardiography in 75.7% (227/300) patients with severe AS. With BAV diagnosis during operation as gold standard, the accuracy of transthoracic echocardiography in identifying BAV was 89.4% (203/227). Among 1 371 patients with severe AS, the percentage of BAV in patients aged <40 years, aged 40-59 years, aged 60-69 years, aged 70-79 years and aged ≥ 80 years was 60.0% (57/95), 57.5% (262/456), 42.7% (184/431), 43.2% (133/308) and 21.0% (17/81), respectively. Incidence of BAV in patients with degenerative calcific valve was significant higher than in those with rheumatic heart disease (44.3% (552/1 246) vs. 4.0% (3/76), P<0.01). Proportion of combined aortic regurgitation ≥ grade 2 was significantly lower, ascending aortic diameter was larger and left ventricular end-diastolic dimension was smaller in BAV patients compared to severe AS patients with tricuspid valves (all P<0.01), while aortic valve annuals diameter and accompanying cardiovascular diseases between BAV and tricuspid aortic valve groups were similar (all P>0.05).</p><p><b>CONCLUSIONS</b>Transthoracic echocardiography could accurately identify aortic valve structures in about 76% patients. BAV is common in severe AS patients across all ages. These results provide important information for the popularization of TVAR.</p>

Artery bypass surgery and endovascular treatment for subclavian arterial sclerosis occlusion disease / 中华普通外科杂志

Objective To investigate the safety and medium-and long-term effects of endovascular stenting,axilloaxillary bypass (AAB),carotid-subclavian bypass (CSB) in patients of subclavian arterial occlusion.Method From 2001 to 2013,311 consecutive patients with subclavian arteriosclerosis obliterans were treated with endovascular stenting (n =191),axilloaxillary bypass (n =96) or carotidsubclavian bypass(n =32).We collected patients' medical data,calculated patency of the graft or stent with life-table method and compared patency between three approaches with Log-rank.Results The incidence of perioperative complications was 4.1％ in the stenting group vs.11.5％ in AAB group vs.18.7％ in CSB group.There was significant statistical differences between the stenting group and bypass group about the incidence of perioperative complications.The primary patency rates at 1,3 and 5 years were 90.3％,84％,81.6％ in stenting group vs.95.3％,92.6％,88.9％ for AAB group vs.100％,96.4％,96.4％ for CSB group.There was significant statistical differences between the stenting group and bypass group about the primary patency rates.Conclusions Both endovascular stenting and extrathoracic surgical bypass are safe and effective treatments for subclavian arteriosclerosis obliterans.However,effect of extrathoracic surgical bypass is more durable in the medium-and long-term.